Cargando…
7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
OBJECTIVE: To assess the ability of ultra-high-field MRI to distinguish early progressive multifocal leukoencephalopathy (PML) from multiple sclerosis (MS) lesions in a rare case of simultaneous presentation of natalizumab–associated PML and ongoing MS activity. METHODS: Advanced neuroimaging includ...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630686/ https://www.ncbi.nlm.nih.gov/pubmed/26568970 http://dx.doi.org/10.1212/NXI.0000000000000171 |
_version_ | 1782398748563865600 |
---|---|
author | Sinnecker, Tim Othman, Jalal Kühl, Marc Mekle, Ralf Selbig, Inga Niendorf, Thoralf Kunkel, Annett Wienecke, Peter Kern, Peter Paul, Friedemann Faiss, Juergen Wuerfel, Jens |
author_facet | Sinnecker, Tim Othman, Jalal Kühl, Marc Mekle, Ralf Selbig, Inga Niendorf, Thoralf Kunkel, Annett Wienecke, Peter Kern, Peter Paul, Friedemann Faiss, Juergen Wuerfel, Jens |
author_sort | Sinnecker, Tim |
collection | PubMed |
description | OBJECTIVE: To assess the ability of ultra-high-field MRI to distinguish early progressive multifocal leukoencephalopathy (PML) from multiple sclerosis (MS) lesions in a rare case of simultaneous presentation of natalizumab–associated PML and ongoing MS activity. METHODS: Advanced neuroimaging including 1.5T, 3T, and 7T MRI with a spatial resolution of up to 0.08 mm(3) was performed. RESULTS: 7T MRI differentiated between PML-related and MS-related brain damage in vivo. Ring-enhancing MS plaques displayed a central vein, whereas confluent PML lesions were preceded by punctate or milky way–like T2 lesions. CONCLUSIONS: Given the importance of early diagnosis of treatment-associated PML, future systematic studies are warranted to assess the value of highly resolving MRI in differentiating between early PML- and MS-induced brain parenchymal lesions. |
format | Online Article Text |
id | pubmed-4630686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-46306862015-11-13 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study Sinnecker, Tim Othman, Jalal Kühl, Marc Mekle, Ralf Selbig, Inga Niendorf, Thoralf Kunkel, Annett Wienecke, Peter Kern, Peter Paul, Friedemann Faiss, Juergen Wuerfel, Jens Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To assess the ability of ultra-high-field MRI to distinguish early progressive multifocal leukoencephalopathy (PML) from multiple sclerosis (MS) lesions in a rare case of simultaneous presentation of natalizumab–associated PML and ongoing MS activity. METHODS: Advanced neuroimaging including 1.5T, 3T, and 7T MRI with a spatial resolution of up to 0.08 mm(3) was performed. RESULTS: 7T MRI differentiated between PML-related and MS-related brain damage in vivo. Ring-enhancing MS plaques displayed a central vein, whereas confluent PML lesions were preceded by punctate or milky way–like T2 lesions. CONCLUSIONS: Given the importance of early diagnosis of treatment-associated PML, future systematic studies are warranted to assess the value of highly resolving MRI in differentiating between early PML- and MS-induced brain parenchymal lesions. Lippincott Williams & Wilkins 2015-10-29 /pmc/articles/PMC4630686/ /pubmed/26568970 http://dx.doi.org/10.1212/NXI.0000000000000171 Text en © 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Article Sinnecker, Tim Othman, Jalal Kühl, Marc Mekle, Ralf Selbig, Inga Niendorf, Thoralf Kunkel, Annett Wienecke, Peter Kern, Peter Paul, Friedemann Faiss, Juergen Wuerfel, Jens 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
title | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
title_full | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
title_fullStr | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
title_full_unstemmed | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
title_short | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
title_sort | 7t mri in natalizumab-associated pml and ongoing ms disease activity: a case study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630686/ https://www.ncbi.nlm.nih.gov/pubmed/26568970 http://dx.doi.org/10.1212/NXI.0000000000000171 |
work_keys_str_mv | AT sinneckertim 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT othmanjalal 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT kuhlmarc 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT mekleralf 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT selbiginga 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT niendorfthoralf 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT kunkelannett 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT wieneckepeter 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT kernpeter 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT paulfriedemann 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT faissjuergen 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy AT wuerfeljens 7tmriinnatalizumabassociatedpmlandongoingmsdiseaseactivityacasestudy |